Form 4 for DXCM Dexcom
Accepted 2023-04-20 00:00:00 ET · period of report 2023-04-20 · accession 0001093557-23-000110 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-04-20 | 2023-04-20 | DXCM | Leach Jacob Steven | EVP CTO | S - Sale | $125.00 | -30.8K | 259.6K | -11% | -$3.85M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-04-20 | S | D | 30,764 | $125.00 | 259,613 | D | — | — | (F1) On December 5, 2022, Mr. Leach adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Leach. The shares set forth above were sold pursuant to the 10b5-1 Plan. The shares set forth above were sold pursuant to the 10b5-1 Plan that was intended to comply with prior version of Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended. (F2) Included in this number are 64,633 unvested restricted stock units, 25,397 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 17,976 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 9,560 of which were granted on March 8, 2021 and shall vest through March 8, 2024. |